FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Hemophilia Treatment Market Overview:

According to FutureWise analysis the market for hemophilia treatment in 2023 is US$ 12.29 billion, and is expected to reach US$ 18.46 billion by 2031 at a CAGR of 5.22%.

Haemophilia is an inherited medical condition that affects how blood clots, causing irregular clotting. After an injury, surgery, or dental work leads to spontaneous and profuse bleeding, easy bruising, and oozing. It is brought on by a congenital deficit of a coagulation factor, which inhibits blood clotting since there aren't enough blood-clotting proteins. Treatment options include prescription drugs, hormone replacement treatment, and plasma or clotting factor injections. The goal of treatment is to prevent problems and replace lost proteins.

Haemophilia A patient will bleed more than usual following an operation, surgery, or dental procedure. A lack of a protein called factor VIII leads to hemophilia A. Replacement therapy is the most typical treatment for clotting factor VIII injection or drip into a vein. According to the National Centre for Biotechnology Information (NCBI), emicizumab is now the only approved nonfactor medication that treats venous access problems, recurrent bleeding, and other problems. Additionally, this course of treatment is advised for individuals taking inhibitors and getting surgery to stop bleeding. Following recent developments, these novel medications demonstrate potential hemostatic properties and significantly reduce bleeding episodes in hemophilia patients, whether they use inhibitors or not. The increased prevalence of hemophilia globally would be a key factor in expanding the market's growth rate.

FutureWise Market Research has published a report that provides an insightful analysis of hemophilia treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the hemophilia treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

Major players included in the Hemophilia Treatment market:

Spark Therapeutics,
Novo Nordisk,
Pfizer Inc,
Bayer AG,
CSL Behring,
Baxter,
Kedrion SPA,
Grifols SA,
Octapharma AG,
Hospira, Inc.

Recent developments by key players in Hemophilia Treatment Market:

In March 2022-First dosage of FLT180a was administered to a patient in the Phase 1/2 B-LIEVE dose-confirmation clinical trial by Freeline Therapeutics Holdings plc for the treatment of haemophilia B, a crippling genetic bleeding illness brought on by a lack in the clotting factor IX protein.

The disease's prevalence is anticipated to drive market growth for hemophilia treatments. Government officials are also introducing new products to improve the therapeutic management of hemophilia. Therefore, an increase in product approvals is anticipated to help this market grow. The National Haemophilia Foundation (NHF) works to educate the public about the signs, symptoms, diagnosis, and care of hemophilia A. Thus, rising disease awareness is anticipated to further fuel market growth. Moreover, major market players are profiting from lucrative expansion potential due to the illness's increasing diagnosis rate and the rising acceptance of hemophilia-preventative treatments. Additionally, regulatory organizations in many countries are launching several campaigns to increase public awareness of the benefits of early diagnosis and the necessity of adhering to the proper procedures to make it simpler to screen new-borns earlier, which is boosting the market. Organizations are also spending more on research and development (R&D) projects due to the lack of therapeutic options. Leading industry players are also focusing on developing technologically advanced diagnostic tools and treatments to increase the efficacy and accuracy of hemophilia therapy. The market is estimated to be propelled by significant investments in the international development of specialized hemophilia treatment centers (HTCs). However, the high cost of the accompanying treatments is expected to restrict the market growth rate for hemophilia. According to the National Haemophilia Foundation, the average annual cost of hemophilia therapy is more than $300,000. This substantially impacts operating margins, especially in the context of capitated reimbursement. The high cost of clotting factor therapy may inhibit market expansion in underdeveloped nations with low incomes. The hemophilia market A therapies, on the other hand, will struggle because of the inadequate status of the healthcare system in developing countries and a lack of skilled professionals. Rigid government rules and a lack of knowledge about the treatment will limit and hinder the market's growth rate.

Hemophilia Treatment Market Segmentation:

By Product

Plasma derived coagulation factor concentrates
- Factor VIII
- Factor IX
- Factor XIII
- Activated prothrombin complex concentrate
- Von willebrand factor
Recombinant coagulation factor concentrates
- Factor VIII
- Factor IX
- Von willebrand factor
Desmopressin
Antifibrinolytic agents

By Type

Hemophilia A
Hemophilia B
Hemophilia C

By Region

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The therapeutic advances in hemophilia, which resulted in a wave of new FDA-approved agents and rising consumer awareness about technologically advanced products, the rising prevalence of hemophilia, and the existence of a sizable patient pool are the main factors propelling the demand of the hemophilia market in the region. Additionally based on type; hemophilia A holdsq highest market share. The most prevalent severe bleeding disorder is hemophilia A. Replacement therapy, which supplies the deficient coagulation factor, has been the cornerstone of care for preventing and treating it. Therefore, this market is anticipated to grow due to the increase in research into gene therapies for hemophilia A.

Competitive Landscape:

Tier 1 players- established companies in the market with major market share
Tier 2 players
New Entrants
Emerging players which are growing rapidly

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Hemophilia Treatment Market By Product, By Type, and By Region.
To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1. Years Considered for the Study
  3.2. Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1. Secondary Data
  1.1.1. Key Data from Secondary Sources
  1.2. Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Global Hemophilia Treatment Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Global Hemophilia Treatment Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Hemophilia Treatment Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Hemophilia Treatment Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Global Hemophilia Treatment Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Plasama derived coagulation factor concentrates
  1.1. Factor VIII
  1.2. Factor IX
  1.3. Factor XIII
  1.4. Activated prothrombin complex concentrate
  1.5. Von willebrand factor
  2. Recombinant coagulation factor concentrates
  2.1. Factor VIII
  2.2. Factor IX
  2.3. Von willebrand factor
  3. Desmopressin
  4. Antifibrinolytic agents
8. Global Hemophilia Treatment Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Hemophilia A
  2. Hemophilia B
  3. Hemophilia C
9. North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
10. Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
11. Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
12. Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
13. Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
- 1. Spark Therapeutics
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Novo Nordisk
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Pfizer Inc
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Bayer AG
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. CSL Behring
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Baxter
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Kedrion SPA
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Grifols SA
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Octapharma AG
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  10. Hospira, Inc.
  10.1. Company Overview
  10.2. Product Portfolio
  10.3. SWOT Analysis
  10.4. Financial Overview
  10.5. Strategic Overview
15. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
16. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients